Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters

摘要: FOLFIRINOX regimen is commonly used in colorectal and more recently pancreatic cancer. However, induces significant dose-limiting toxic effects leading to empirical dose reduction sometimes treatment discontinuation. Model-based optimization might help improving patients’ outcome. As a first step, the current review aims at bringing together all published population pharmacokinetics models for anticancer drugs. A literature search was conducted PubMed database from inception February 2018, using following terms: pharmacokinetic(s), irinotecan, oxaliplatin, fluorouracil, FOLFIRI, FOLFOX, FOLFIRINOX. Only articles displaying nonlinear mixed effect were included. Study description, pharmacokinetic parameter values influential covariates are reported. For each model, typical profile simulated standard protocol. The compounds have been studied only separately so far. total of six retained 5-fluorouracil, 6 oxaliplatin 5 irinotecan (also including metabolites). Either one- or two-compartment described while two- three-compartment reported pharmacokinetics. Non-linear elimination 5-fluorouracil. Sex body size found as molecules some publications. Despite differences model structures values, profiles subsequent exposure consistent between studies. allows global understanding pharmacokinetics, will provide basis further development pharmacokinetics–pharmacodynamics–toxicity model-driven protocol reach best benefit-to-risk ratio.